menu
FR | EN
Digital Healthcare Community
Certified Medical Tourism ProfessionalBest Medical Travel Agency 2015Best use of technology in Medical Travel 2017

News

2 results
French medical cannabis trial shows promise

05/10/2021

Pain medicines produced from cannabis oil have the potential to significantly improve the lives of patients, a French study has found. According to the initial results from a trial that began in a French hospital back in March, using medical cannabis for pain relief is effective. Psychiatrist Dr Nicolas Authier, Chair of the Scientific Committee on Medical Cannabis, is in charge of the experiment being conducted at the University Hospital of Clermont-Ferrand in central France. Dr Authier picked 20 suitable patients for participation in the trial. One patient, Mounir, 47, who suffered a stroke aged 21 and consequently struggled with painkiller addiction in an attempt to manage his neuropathic pain, told France 3: “I'm not yet completely relieved of the pain. There is some still, but it is nothing like what I felt before.” The trial is part of a two-year nationwide experiment in France that is primarily designed to evaluate the best conditions of access to medical cannabis. Depending on the patient and their condition, medical cannabis can deliver mild to significant relief. However, some patients have experienced no improvement, while others experienced more undesirable effects than therapeutic ones. Dr Authier hopes that medical cannabis can be legalized for patients whose suffering is poorly relieved by conventional treatments. Image by Julia Teichmann from Pixabay

Medical cannabis trial to begin in hospitals across France in January

08/07/2021

Thousands of patients with a range of different ailments are due to participate in medical cannabis trials in January next year. Up to 3,000 individuals with illnesses such as epilepsy, neuropathic pain, multiple sclerosis and chemotherapy side-effects, as well as those on palliative care will be trialled with medical cannabis, which will be provided in oil form for oral administration, or as dried leaves for inhalation. Smoking will not be allowed because of its ill health effects. Medical cannabis will only be prescribed “as a last resort” and the trial patients will be put forward by a specialist, neurologist or pain control doctor. Hospitals across France will take part. The Agence Nationale de Sécurité du Médicament (ANSM) delayed the start of the trial until January 2021 so that a national electronic patient monitoring and support network could be set up. The trial was also pushed back while the ANSM found suitable suppliers. ANSM said the purpose of the trial is not to establish how effective medical cannabis is for treating certain conditions, but rather to gauge supply and follow-up. The benefits of medical cannabis are well known and highlighted by the fact its name has been changed from “therapeutic cannabis”, which implied general benefits, to “medical cannabis”. *Image by NickyPe from Pixabay

expand_less